Bone Health and Denosumab Discontinuation in Oncology Populations

被引：2
|
作者：
Cheung, Yee-Ming Melody [1 ,2 ,3 ]
Morgans, Alicia [2 ,4 ]
Hamnvik, Ole-Petter Riksfjord [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave,RFB 2, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Melbourne, Austin Hosp, Dept Med, Endocrine Unit, Melbourne, Vic, Australia
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ONCOLOGIST | 2022年 / 27卷 / 12期
关键词：
bone health; cancer; denosumab discontinuation; multiple vertebral fractures; rebound phenomenon; ZOLEDRONIC ACID; MINERAL DENSITY; BREAST-CANCER; VERTEBRAL FRACTURES; PROSTATE-CANCER; DOUBLE-BLIND; POSITION STATEMENT; METASTASES; PREVENTION; THERAPY;
D O I：
10.1093/oncolo/oyac213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Managing bone health after denosumab cessation is a commonly encountered challenge. Although the "rebound phenomenon" is generally recognized by endocrinologists in the context of osteoporosis, it is not as widely understood in the context of bone metastases and cancer. This commentary reviews the evidence on the efficacy and safety of various bone health agents in mitigating the "rebound phenomenon" in cancer populations.
引用
收藏
页码：998 / 1003
页数：6
相关论文
共 50 条
  • [1] Impact of Discontinuation of Denosumab on Bone Health in Breast Cancer Patients
    Tannenbaum, Susan
    Soto, Alvaro Alvarez
    Taxel, Pamela
    CANCER RESEARCH, 2024, 84 (09)
  • [2] EFFECTS OF DENOSUMAB DISCONTINUATION ON BONE HISTOLOGY AND HISTOMORPHOMETRY
    Brown, J. P.
    Dempster, D. W.
    Ding, B.
    Dent, R.
    San Martin, J.
    Wagman, R. B.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 134 - 135
  • [3] Effect of risedronate on bone loss at discontinuation of denosumab
    Laroche, Michel
    Couture, Guillaume
    Ruyssen-Witrand, Adeline
    Constantin, Arnaud
    Degboe, Yannick
    BONE REPORTS, 2020, 13
  • [4] Bone loss after discontinuation of denosumab: the devil is in the details
    Minisola, Salvatore
    Cipriani, Cristiana
    Colangelo, Luciano
    Pepe, Jessica
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (01) : 3 - 7
  • [5] Denosumab Discontinuation
    Anne Sophie Sølling
    Elena Tsourdi
    Torben Harsløf
    Bente L Langdahl
    Current Osteoporosis Reports, 2023, 21 : 95 - 103
  • [6] Denosumab Discontinuation
    Solling, Anne Sophie
    Tsourdi, Elena
    Harslof, Torben
    Langdahl, Bente L.
    CURRENT OSTEOPOROSIS REPORTS, 2023, 21 (01) : 95 - 103
  • [7] Bisphophonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
    Belen Zanchetta, Maria
    Pelegrin, Carolina
    Silveira, Fernando
    Bogado, Cesar
    Zanchetta, Jose
    Salerni, Helena
    Costanzo, Pablo
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 114 - 115
  • [8] Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis
    Zeytinoglu, Meltem
    Naaman, Sandra C.
    Dickens, Laura T.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2021, 50 (02) : 205 - 222
  • [9] Bone Matrix Mineralization After Denosumab Treatment Discontinuation.
    Brown, Jacques
    Dempster, David
    Yue, Susan
    Rizzo, Sebastien
    Farlay, Delphine
    Wagman, Rachel
    Yin, Xiang
    Boivin, Georges
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S406 - S406
  • [10] EVOLUTION OF TURNOVER BONE MARKERS AFTER DENOSUMAB DISCONTINUATION: A PRELIMINARY STUDY
    Lamy, O. L.
    Hans, D. H.
    Rodriguez, E. G. -R. Gonzalez
    Aubry-Rozier, B. A. -R.
    Stoll, D. S.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S526 - S526
12345